This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

This study has been completed.
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Cal Cohen, Community Research Initiative of New England Identifier:
First received: June 30, 2009
Last updated: March 14, 2013
Last verified: March 2013
Results First Received: February 5, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV
Interventions: Drug: atazanavir/raltegravir
Drug: atazanavir/tenofovir/emtricitabine

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Control Arm atazanavir/tenofovir/emtricitabine : Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
Intervention Arm No.1 atazanavir/raltegravir: switch to atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
Intervention Arm No.2 atazanavir/raltegravir: switch to atazanavir 300mg twice daily plus raltegravir 400mg twice daily
Total Total of all reporting groups

Baseline Measures
   Control Arm   Intervention Arm No.1   Intervention Arm No.2   Total 
Overall Participants Analyzed 
[Units: Participants]
 14   15   14   43 
[Units: Years]
Mean (Standard Deviation)
 43.5  (11.6)   47.6  (11.5)   46.6  (6.6)   45.9  (10.1) 
[Units: Participants]
Female   2   2   1   5 
Male   12   13   13   38 
Ethnicity (NIH/OMB) 
[Units: Participants]
Hispanic or Latino   6   2   5   13 
Not Hispanic or Latino   8   13   9   30 
Unknown or Not Reported   0   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
American Indian or Alaska Native   0   0   0   0 
Asian   1   0   0   1 
Native Hawaiian or Other Pacific Islander   0   0   0   0 
Black or African American   3   3   3   9 
White   9   12   11   32 
More than one race   0   0   0   0 
Unknown or Not Reported   1   0   0   1 
Region of Enrollment 
[Units: Participants]
United States   14   15   14   43 
Mean CD4 
[Units: Cells/mm3]
Mean (Standard Deviation)
 544.6  (197.7)   518.5  (198.9)   533.9  (198.3)   532.0  (193.8) 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maintenance of Virologic Suppression   [ Time Frame: 48 weeks ]

2.  Secondary:   The Difference in CD4 From Baseline to Week 48   [ Time Frame: Baseline and Week 48 ]

3.  Secondary:   The Change in Adherence to Study Treatment Arm From Baseline to Week 48   [ Time Frame: Baseline and Week 48 ]

4.  Secondary:   Change in Quality of Life From Baseline to 48 Weeks of Study Treatment   [ Time Frame: baseline and 48 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information